Effect of niacin on atherosclerotic cardiovascular disease.

Journal Article (Journal Article;Review)

Niacin has been studied in 6 major clinical trials with cardiovascular endpoints. The Coronary Drug Project (CDP) was the largest of these trials and the only one to use niacin monotherapy affecting cardiovascular outcomes: recurrent myocardial infarction and cerebrovascular events were significantly decreased. After long-term (15 years) follow-up, total mortality was also found to be decreased. The other 5 trials used varying combinations of niacin with other pharmacologic agents, examining coronary and total mortality, coronary events, and angiographic progression/regression. Significant benefit was found in all trials except for one in patients with normal cholesterol levels at entry. Thus, the use of niacin to prevent or treat atherosclerotic cardiovascular disease is based on strong and consistent evidence from clinical trials.

Full Text

Duke Authors

Cited Authors

  • Guyton, JR

Published Date

  • December 17, 1998

Published In

Volume / Issue

  • 82 / 12A

Start / End Page

  • 18U - 23U

PubMed ID

  • 9915658

International Standard Serial Number (ISSN)

  • 0002-9149

Digital Object Identifier (DOI)

  • 10.1016/s0002-9149(98)00767-x


  • eng

Conference Location

  • United States